Discovery and development of new biological drugs addressing significant unmet medical needs in the areas of difficult-to-treat diseases (e.g., cancers, inflammatory/immune disease, and rare diseases) More
Sankyo Co. Ltd. is currently the second largest pharmaceutical company in Japan. It is famous as the founder of HMG-CoA reductase inhibitor anti-hyperlipidemia drugs. More
Specialists in pharmaceutical alliances in Japan and North America, identifying licensing opportunities, and guiding early stage corporate development. More